Nektar Therapeutics CFO/COO steps down; Jillian Thomsen named CFO; CCO separation detailed

NEKTAR THERAPEUTICS

Gil Labrucherie steps down as CFO and COO effective July 1, 2022.
Jillian Thomsen promoted from SVP Finance and CAO to SVP and CFO effective July 1, 2022.
John Northcott, SVP and CCO, separated June 30, 2022; receives $921,206 lump sum severance.
Northcott gets consulting retainer of $20k/month for up to 60 hours, $335/hr thereafter through Dec 31, 2022.
Vested options for Northcott remain exercisable until June 30, 2023; no further vesting of unvested awards.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gil Labrucherie

Chief Financial Officer and Chief Operating Officer

NKTR · NEKTAR THERAPEUTICS

Effective: 2022-07-01
Successor: Jillian Thomsen
Filed: July 1, 2022, 7:59 PM ET

On July 1, 2022, Nektar Therapeutics (the “Company”) announced that Gil Labrucherie will step down as Chief Financial Officer and Chief Operating Officer of the Company, effective as of July 1, 2022.

Departed

John Northcott

Senior Vice President and Chief Commercial Officer

NKTR · NEKTAR THERAPEUTICS

Effective: 2022-06-30
Filed: July 1, 2022, 7:59 PM ET

On April 25, 2022 (the “Notice Date”), the Company announced that John Northcott will step down from the role of Senior Vice President and Chief Commercial Officer of the Company.

Role change

Jillian Thomsen

Senior Vice President and Chief Financial Officer

NKTR · NEKTAR THERAPEUTICS

Effective: 2022-07-01
Filed: July 1, 2022, 7:59 PM ET

On July 1, 2022, the Company announced the promotion of Jillian Thomsen, who currently serves as Senior Vice President, Finance and Chief Accounting Officer, to the position of Senior Vice President and Chief Financial Officer, effective as of July 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gil Labrucherie departed as Chief Financial Officer and Chief Operating Officer at NEKTAR THERAPEUTICS.

Action: step down
Role: Chief Financial Officer and Chief Operating Officer

Exact text from the filing

On July 1, 2022, Nektar Therapeutics (the “Company”) announced that Gil Labrucherie will step down as Chief Financial Officer and Chief Operating Officer of the Company, effective as of July 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Northcott departed as Senior Vice President and Chief Commercial Officer at NEKTAR THERAPEUTICS.

Action: step down
Role: Senior Vice President and Chief Commercial Officer

Exact text from the filing

On April 25, 2022 (the “Notice Date”), the Company announced that John Northcott will step down from the role of Senior Vice President and Chief Commercial Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jillian Thomsen changed role as Senior Vice President and Chief Financial Officer at NEKTAR THERAPEUTICS.

Action: promoted
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

On July 1, 2022, the Company announced the promotion of Jillian Thomsen, who currently serves as Senior Vice President, Finance and Chief Accounting Officer, to the position of Senior Vice President and Chief Financial Officer, effective as of July 1, 2022.

View on SEC.gov

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-22-036694

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.